Clearmind Medicine Common Stock Fundamentals
CMND Stock | USD 1.33 0.01 0.75% |
Clearmind Medicine Common fundamentals help investors to digest information that contributes to Clearmind Medicine's financial success or failures. It also enables traders to predict the movement of Clearmind Stock. The fundamental analysis module provides a way to measure Clearmind Medicine's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Clearmind Medicine stock.
At present, Clearmind Medicine's Cost Of Revenue is projected to increase significantly based on the last few years of reporting. The current year's Total Operating Expenses is expected to grow to about 10.6 M, whereas Gross Profit is projected to grow to (48.2 K). Clearmind | Select Account or Indicator |
Clearmind Medicine Common Company Shares Outstanding Analysis
Clearmind Medicine's Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current Clearmind Medicine Shares Outstanding | 4.07 M |
Most of Clearmind Medicine's fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Clearmind Medicine Common is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Clearmind Shares Outstanding Historical Pattern
Today, most investors in Clearmind Medicine Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Clearmind Medicine's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's shares outstanding growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Clearmind Medicine shares outstanding as a starting point in their analysis.
Clearmind Medicine Shares Outstanding |
Timeline |
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
Competition |
Clearmind Common Stock Shares Outstanding
Common Stock Shares Outstanding |
|
Based on the latest financial disclosure, Clearmind Medicine Common has 4.07 M of shares currently outstending. This is 97.74% lower than that of the Biotechnology sector and 96.19% lower than that of the Health Care industry. The shares outstanding for all United States stocks is 99.29% higher than that of the company.
Clearmind Medicine Common Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Clearmind Medicine's current stock value. Our valuation model uses many indicators to compare Clearmind Medicine value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Clearmind Medicine competition to find correlations between indicators driving Clearmind Medicine's intrinsic value. More Info.Clearmind Medicine Common is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At present, Clearmind Medicine's Return On Equity is projected to drop based on the last few years of reporting. Comparative valuation analysis is a catch-all technique that is used if you cannot value Clearmind Medicine by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Clearmind Shares Outstanding Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Clearmind Medicine's direct or indirect competition against its Shares Outstanding to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Clearmind Medicine could also be used in its relative valuation, which is a method of valuing Clearmind Medicine by comparing valuation metrics of similar companies.Clearmind Medicine is currently under evaluation in shares outstanding category among its peers.
Clearmind Medicine Current Valuation Drivers
We derive many important indicators used in calculating different scores of Clearmind Medicine from analyzing Clearmind Medicine's financial statements. These drivers represent accounts that assess Clearmind Medicine's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Clearmind Medicine's important valuation drivers and their relationship over time.
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Market Cap | 11.3K | 16.8K | 21.8K | 466.4K | 419.8K | 440.8K | |
Enterprise Value | 10.6K | (313.0K) | (4.6M) | 343.0K | 394.5K | 414.2K |
Clearmind Fundamentals
Return On Equity | -2.68 | ||||
Return On Asset | -0.58 | ||||
Current Valuation | (2.2 M) | ||||
Shares Outstanding | 4.07 M | ||||
Shares Owned By Institutions | 17.31 % | ||||
Number Of Shares Shorted | 316.6 K | ||||
Price To Earning | (750.00) X | ||||
Price To Book | 1.56 X | ||||
EBITDA | (8.71 M) | ||||
Net Income | (6.23 M) | ||||
Cash And Equivalents | 1.65 K | ||||
Total Debt | 3.61 M | ||||
Current Ratio | 0.03 X | ||||
Book Value Per Share | 0.87 X | ||||
Cash Flow From Operations | (4.56 M) | ||||
Short Ratio | 0.58 X | ||||
Earnings Per Share | (1.23) X | ||||
Beta | -1.51 | ||||
Market Capitalization | 5.41 M | ||||
Total Asset | 4.32 M | ||||
Retained Earnings | (13.63 M) | ||||
Working Capital | 824.76 K | ||||
Net Asset | 4.32 M |
About Clearmind Medicine Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Clearmind Medicine Common's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Clearmind Medicine using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Clearmind Medicine Common based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Last Reported | Projected for Next Year | ||
Cost Of Revenue | 64.8 K | 68 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Clearmind Medicine Common is a strong investment it is important to analyze Clearmind Medicine's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Clearmind Medicine's future performance. For an informed investment choice regarding Clearmind Stock, refer to the following important reports:Check out Clearmind Medicine Piotroski F Score and Clearmind Medicine Altman Z Score analysis. You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Clearmind Medicine. If investors know Clearmind will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Clearmind Medicine listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.23) | Return On Assets (0.58) | Return On Equity (2.68) |
The market value of Clearmind Medicine Common is measured differently than its book value, which is the value of Clearmind that is recorded on the company's balance sheet. Investors also form their own opinion of Clearmind Medicine's value that differs from its market value or its book value, called intrinsic value, which is Clearmind Medicine's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Clearmind Medicine's market value can be influenced by many factors that don't directly affect Clearmind Medicine's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Clearmind Medicine's value and its price as these two are different measures arrived at by different means. Investors typically determine if Clearmind Medicine is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Clearmind Medicine's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.